Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis

被引:350
|
作者
Musso, Giovanni [1 ]
Gambino, Roberto [2 ]
Cassader, Maurizio [2 ]
机构
[1] Gradenigo Hosp, I-10132 Turin, Italy
[2] Univ Turin, Dept Med Sci, I-10124 Turin, Italy
关键词
NAFLD; NASH; Lipotoxic; Free cholesterol; Cholesterol homeostasis; ER stress; FATTY LIVER-DISEASE; PICK C1-LIKE 1; ENDOPLASMIC-RETICULUM STRESS; HEPATIC STELLATE CELLS; INSULIN-RECEPTOR SUBSTRATE-1; GENOME-WIDE ASSOCIATION; X-RECEPTOR; LIPID-METABOLISM; GENE-EXPRESSION; DIETARY-CHOLESTEROL;
D O I
10.1016/j.plipres.2012.11.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Emerging experimental and human evidence has linked altered hepatic cholesterol homeostasis and free cholesterol (FC) accumulation to the pathogenesis of non-alcoholic steatohepatits (NASH). This review focuses on cellular mechanisms of cholesterol toxicity involved in liver injury and on alterations in cholesterol homeostasis promoting hepatic cholesterol overload in NASH. FC accumulation injures hepatocytes directly, by disrupting mitochondrial and endoplasmic reticulum (ER) membrane integrity, triggering mitochondrial oxidative injury and ER stress, and by promoting generation of toxic oxysterols, and indirectly, by inducing adipose tissue dysfunction. Accumulation of oxidized LDL particles may also activate Kupffer and hepatic stellate cells, promoting liver inflammation and fibrogenesis. Hepatic cholesterol accumulation is driven by a deeply deranged cellular cholesterol homeostasis, characterized by elevated cholesterol synthesis and uptake from circulating lipoproteins and by a reduced cholesterol excretion. Extensive dysregulation of cellular cholesterol homeostasis by nuclear transcription factors sterol regulatory binding protein (SREBP)-2, liver X-receptor (LXR)-alpha and farnesoid X receptor (FXR) plays a key role in hepatic cholesterol accumulation in NASH. The therapeutic implications and opportunities for normalizing cellular cholesterol homeostasis in these patients are also discussed. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:175 / 191
页数:17
相关论文
共 50 条
  • [31] Drugs and non-alcoholic steatohepatitis
    Farrell, GC
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 132 - 139
  • [32] Obesity and non-alcoholic steatohepatitis
    García-Monzón, C
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 117 - 123
  • [33] Saroglitazar for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 698 - 698
  • [34] Mechanisms of non-alcoholic steatohepatitis
    McClain, CJ
    Mokshagundam, PL
    Barve, SS
    Song, ZY
    Hill, DB
    Chen, T
    Deaciuc, I
    ALCOHOL, 2004, 34 (01) : 67 - 79
  • [35] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    LANCET, 2001, 358 (9285): : 893 - 894
  • [36] Selonsertib for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 852 - 852
  • [37] A central role for cholesterol metabolism and inflammation during the inhibition of non-alcoholic steatohepatitis with a synthetic PPARα agonist
    Wouters, Kristiaan
    van Bilsen, Marc
    Bieghs, Veerle
    van Gorp, Patrick J.
    Lutjohann, Dieter
    Kerksiek, Anja
    Staels, Bart
    Hofker, Marten H.
    Shiri-Sverdlov, Ronit
    CHEMISTRY AND PHYSICS OF LIPIDS, 2008, 154 : S56 - S56
  • [38] Treatment of non-alcoholic steatohepatitis
    Angulo, P
    Lindor, KD
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 797 - 810
  • [39] Fructose and Non-Alcoholic Steatohepatitis
    Roeb, Elke
    Weiskirchen, Ralf
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [40] Diagnosis of non-alcoholic steatohepatitis
    James, OFW
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 34 - 39